Vicc

A new tool to observe cell behavior has revealed surprising clues about how cancer cells respond to therapy, and may offer a way to further refine personalized cancer treatments. Read More

Vanderbilt-Ingram Cancer Center researchers have identified how one of the genes most commonly mutated in lung cancer may promote such tumors. Read More

Investigators from Vanderbilt-Ingram Cancer Center and three other cancer centers have identified a link between a rare genetic variant and the risk of developing glioma. Read More

Carlos Arteaga, M.D., associate director for Clinical Research and director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been named to the Scientific Advisory Board of the Susan G. Komen for the Cure Breast Cancer Research Foundation. Read More

Mohamed Hassanein, Ph.D., research instructor in Pulmonary Medicine, has received a Career Development Award from the LUNGevity Foundation to work on the development of noninvasive tests to help diagnose lung cancer. Read More

Two proteins that act in opposing directions – one that promotes cancer and one that suppresses cancer — regulate the same set of genes in prostate cancer, Vanderbilt-Ingram Cancer Center researchers have found. Read More

Vanderbilt-Ingram Cancer Center has initiated tumor mutation testing for a limited number of patients with metastatic colorectal cancer. Read More

The Vanderbilt-Ingram Cancer Center debuted a new video at its annual celebration of cancer survivors recently. “This Side of Cancer” tells the story of hope and second chances from the point of three cancer survivors. The video can be viewed on YouTube. Contact:… Read More

Chin Chiang, Ph.D., professor of Cell and Developmental Biology and member of the Vanderbilt-Ingram Cancer Center faculty, has been awarded a $200,000 grant to study an aggressive form of childhood cancer. Read More

Olympic gold medal skating champion and cancer survivor Scott Hamilton was the keynote speaker at Vanderbilt-Ingram Cancer Center’s annual cancer survivors day event held at the Vanderbilt Student Life Center. Nearly 600 people attended “Going for the Gold: Living Well through Cancer,” which featured activities for cancer… Read More

An experimental drug that activates T-cells and promotes an immune response to fight tumors has shown promising early results in patients with kidney cancer, melanoma and non-small cell lung cancer. Leora Horn, M.D. Vanderbilt-Ingram Cancer Center investigators Leora Horn, M.D., Jeffrey Sosman, M.D., and researchers from several other cancer… Read More

A study led by Vanderbilt-Ingram Cancer Center investigators has identified a gene expression pattern that may explain why chemotherapy prior to surgery isn’t effective against some tumors and suggests new therapy options for patients with specific subtypes of breast cancer. Read More

An experimental melanoma drug may be beneficial for patients not eligible for targeted therapies. Read More

Measuring levels of an enzyme in head and neck tumors may indicate how the tumor will respond to radiation therapy. Read More

Leonard Folgarait, professor of history of art, delivered the keynote address on Mexican photography at the Art History Graduate Student Symposium held at Duke University. Nancy Godleski has been named assistant dean for collections at Central Library. Previously, Godleski was the Kaplanoff Librarian for American History and American Studies at… Read More

Vanderbilt-Ingram Cancer Center investigators have won two of the five global innovation grants awarded by the “GE Healthymagination Cancer Challenge.” Read More

A new study offers clues on why melanoma patients who are treated with oral drugs inhibiting the BRAF gene are at increased risk for developing secondary skin cancers. Read More

Cellular pathways altered by chronic exposure to cigarette smoke may reveal new biomarkers to assess smoking-induced lung cancer risk. Read More

A molecule detectable in urine may be helpful in diagnosing colon cancer. Read More

Investigators from Vanderbilt-Ingram Cancer Center and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival. Read More